Publications by authors named "Shanmei Tan"
Article Synopsis
- The study assessed laparoscopic radical hysterectomy (LRH) outcomes in early-stage, low-risk cervical cancer patients compared to open abdominal radical hysterectomy (OARH).
- In low-risk cases, 5-year overall and progression-free survival rates were similar for LRH (98.6% OS, 97.6% PFS) and OARH (99.3% OS, 98.4% PFS), with no significant differences found.
- Conversely, in high-risk patients, LRH showed lower survival rates compared to OARH, indicating the need for careful surgical approach selection based on risk factors and imaging prior to surgery.
Background: No residual disease (R0 resection) after debulking surgery is the most critical independent prognostic factor for advanced ovarian cancer (AOC). There is an unmet clinical need for selecting primary or interval debulking surgery in AOC patients using existing prediction models.
Methods: RNA sequencing of circulating small extracellular vesicles (sEVs) was used to discover the differential expression microRNAs (DEMs) profile between any residual disease (R0, n = 17) and no residual disease (non-R0, n = 20) in AOC patients.
Background: M2 macrophages play an important role in cancer development. However, the underlying biological fator affecting M2 macrophages infiltration in ovarian cancer (OV) has not been elucidated.
Methods: R software v 4.
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
Exp Cell Res
January 2022
Resistance to platinum and PARP inhibitors represents a major barrier to the long-term survival of ovarian cancer patients. We aim to explore the potential role of chronic stress in drug resistance in ovarian cancer. Leveraging four ovarian cancer with chronic stress (OCCS) mouse models, we explore the therapeutic efficacy of platinum, Niraparib, and Docetaxel treatment in vivo, and compare the efficacy of these anti-tumor drugs in vitro using cell viability assays.
View Article and Find Full Text PDFA phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Gynecol Oncol
February 2018
Objective: Antiangiogenic treatments have been implicated to play a major role in epithelial ovarian cancer (EOC). Apatinib, a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2), is currently being studied in different tumor types and is already used in gastric adenocarcinoma. This study was performed to assess the efficacy and safety of apatinib in patients with recurrent, pretreated EOC.
View Article and Find Full Text PDF